Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

Trial Profile

Phase II Study to Determine the Efficacy and Safety of PIKA Rabies Vaccine Containing the PIKA Adjuvant With an Accelerated Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Nov 2017

At a glance

  • Drugs Rabies vaccine Yisheng Biopharma (Primary) ; Rabies vaccine
  • Indications Rabies
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Yisheng Biopharma
  • Most Recent Events

    • 12 Nov 2017 Primary endpoint (Proportion of subjects with an RVNA titer of 0.5IU/ml at Day 14-non-inferiority) has been met, according to results published in the Vaccine Journal.
    • 12 Nov 2017 Results published in the Vaccine Journal.
    • 03 Nov 2016 Status changed from recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top